Fostering collaborations and the career of a newly recruited pulmonary scientist

促进新聘肺科科学家的合作和职业生涯

基本信息

批准号：
7936154
负责人：
RICHARD J MARTIN
金额：
$ 71.94万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7936154
关键词：
Address Adverse effects Advisory Committees American Architecture Area Arts Asthma Award Basic Science Biology California Cancer Grant Supplements (P30)Candidate Disease Gene Caring Cells Clinical Clinical Medicine Collaborations Commit Communities Community Health Core Facility Critical Care Development Disease Doctor of Philosophy Drug usage Ensure Environment Epithelial Cells Equilibrium Evaluation Faculty Fostering Funding Gene Expression Gene Expression Profiling Genes Glucocorticoid Receptor Glucocorticoids Goals Health Human Resources Immune Internal Medicine Investigation Investments Laboratories Libraries Life Lung Lung diseases Manuscripts Mediating Medicine Methods Modeling Molecular Mus Pathway interactions Patients Physicians Publications Receptor Signaling Recruitment Activity Reporter Research Research Infrastructure Research Personnel Research Proposals Resistance San Francisco Scientist Signal Pathway Signal Transduction Small Interfering RNA Therapeutic Tissues Training Universities Washington Work base career career development cell type clinical practice direct patient care falls follower of religion Jewish improved innovation interest meetings member programs promoter success tool

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of National Jewish Health (NJH) is to improve the lives of patients with lung disease both through direct patient care, and a synergistic combination of clinical, translational and basic research. The general strategy is to recruit physicians and scientists that focus on lung disease and biology, and to foster strong collaborations. Specifically, last fall, NJH undertook a national search for a physician-scientist with an outstanding research background and an interest in airway biology and disease. As a result of this effort, the Pulmonary Division successfully recruited an outstanding, newly independent physician-scientist to join the faculty and conduct research on glucocorticoid signaling. Dr. Anthony Gerber received his MD/Ph.D. at the University of Washington in 1998, and completed his training at the University of California, San Francisco in 2004. He has recently developed an exciting research program on tissue and promoter specific mechanisms of glucocorticoid signaling. This is an area with significant relevance to airway biology and the goals of NJH. Glucocorticoids are among the most widely used drugs in clinical medicine and are central in the treatment of asthma and other immune-mediated diseases. However, severe side effects and resistance complicate their use in clinical practice. A key issue in glucocorticoid receptor (GR) biology and pulmonary therapeutics is to understand the beneficial and harmful effects of glucocorticoid signaling, in particular cell types within the lung, and to define the molecular mechanisms that control these activities. State-of-the-art multiplexed methods to analyze gene expression will be used to address this research area, methods that are broadly applicable to the study of lung disease. With the funds from the PSO award Dr. Gerber's research programs on glucocorticoid signaling will be advanced, collaborations on disease modifying pathways in the lung and multiplexed analysis of gene expression will be facilitated. This will be accomplished by (1) investments in infrastructure for Dr. Gerber's lab and employing skilled personnel to assist with his investigations, (2) integrating tools and methods for multiplexed gene expression analysis into the investigations of other researchers in the division/core, and (3) forming a committee to oversee Dr. Gerber's progress. NJH is at the forefront of the treatment and research of lung and immune-mediated diseases, which afflict millions of Americans. This project will advance the understanding of glucocorticoid signaling, which is central in the treatment of many diseases. It will also foster collaborations among a group of outstanding scientists focused on lung disease.

描述（由申请人提供）：国家犹太健康中心 (NJH) 的长期目标是通过直接患者护理以及临床、转化和基础研究的协同结合来改善肺病患者的生活。总体策略是招募专注于肺部疾病和生物学的医生和科学家，并促进强有力的合作。具体来说，去年秋天，新泽西州卫生局在全国范围内寻找一位具有杰出研究背景并对气道生物学和疾病感兴趣的医师科学家。通过这一努力，肺科成功招募了一位杰出的新独立医师科学家加入教师队伍，开展糖皮质激素信号传导研究。安东尼·格伯博士获得医学博士/博士学位。他于 1998 年在华盛顿大学获得博士学位，并于 2004 年在旧金山加利福尼亚大学完成了培训。他最近开发了一项关于糖皮质激素信号传导的组织和启动子特异性机制的令人兴奋的研究项目。这是一个与气道生物学和 NJH 目标密切相关的领域。糖皮质激素是临床医学中使用最广泛的药物之一，是治疗哮喘和其他免疫介导疾病的核心药物。然而，严重的副作用和耐药性使其在临床实践中的使用变得复杂。糖皮质激素受体 (GR) 生物学和肺部治疗的一个关键问题是了解糖皮质激素信号传导的有益和有害影响，特别是肺内的细胞类型，并确定控制这些活动的分子机制。最先进的多重方法来分析基因表达将用于解决这一研究领域，这些方法广泛适用于肺部疾病的研究。借助 PSO 奖项的资金，Gerber 博士的糖皮质激素信号传导研究项目将得到推进，肺部疾病改变途径和基因表达多重分析方面的合作也将得到促进。这将通过以下方式实现：(1) 投资格伯博士实验室的基础设施并雇用技术人员协助他的研究，(2) 将多重基因表达分析的工具和方法整合到部门/核心其他研究人员的研究中， (3) 成立一个委员会来监督格伯博士的进展。 NJH 处于肺部和免疫介导疾病治疗和研究的前沿，这些疾病困扰着数百万美国人。该项目将增进对糖皮质激素信号传导的理解，糖皮质激素信号传导在许多疾病的治疗中至关重要。它还将促进一群专注于肺部疾病的杰出科学家之间的合作。